Silk Road Medical Inc: M&A transaction — Boston Scientific closes acquisition of Silk Road Medical for $27.50 per share

Silk Road Medical Inc

Merger closed on September 17, 2024; shareholders received $27.50 per share in cash.
Silk Road became a wholly owned subsidiary of Boston Scientific; stock delisted from Nasdaq.
Previous board and officers (including CEO Charles McKhann) replaced by Boston Scientific appointees.
Existing loan agreement with Oxford Finance repaid in full with 1% prepayment fee; success fee paid to Stifel Bank.
Company will file Form 15 to terminate SEC reporting obligations.

item 1.02 item 2.01 item 3.01 item 3.03 item 5.01 item 5.03 item 2.04 item 5.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Silk Road Medical Inc underwent a change of control involving Boston Scientific Corporation for $27.50 in cash (closed 2024-09-17).

Action: change of control
Counterparty: Boston Scientific Corporation
Consideration: $27.50 in cash
Closing: 2024-09-17

Exact text from the filing

prior to the Effective Time (subject to certain customary exceptions specified in the Merger Agreement) was cancelled and converted automatically into the right to receive $27.50 in cash, without interest (the “Merger Consideration”) and subject to applicable taxes. Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised

View on SEC.gov

Browse all m&a transactions →

Source: SEC EDGAR

accession 0001140361-24-041264

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.